Using the laws of thermodynamics to understand how matrix metalloproteinases coordinate the myocardial response to injury

References

• Chiao YA, Dai Q, Zhang J, et al. Multi-analyte profiling reveals matrix metalloproteinase-9 and monocyte chemotactic protein-1 as plasma biomarkers of cardiac aging. Circ Cardiovasc Genet. 2011;4(4):455–462.
   PubMedGoogle Scholar
• Ma Y, Chiao YA, Zhang J, Manicone AM, Jin YF, Lindsey ML. Matrix metalloproteinase-28 deletion amplifies inflammatory and extracellular matrix responses to cardiac aging. Microsc Microanal. 2012;18(1):81–90.
   Web of Science ®Google Scholar
• Yabluchanskiy A, Ma Y, Chiao YA, et al. Cardiac aging is initiated by matrix metalloproteinase-9-mediated endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2014;306(10):H1398–H1407.
   Web of Science ®Google Scholar
• Chiao YA, Ramirez TA, Zamilpa R, et al. Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res. 2012;96(3):444–455.
   Web of Science ®Google Scholar
• Ma Y, Chiao YA, Clark R, et al. Deriving a cardiac ageing signature to reveal MMP-9-dependent inflammatory signalling in senescence. Cardiovasc Res. 2015;106(3):421–431.
   Web of Science ®Google Scholar
• Yousef ZR, Redwood SR, Bucknall CA, Sulke AN, Marber MS. Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study). J Am Coll Cardiol. 2002;40(5):869–876.
   Web of Science ®Google Scholar
• Mathieu E, Lamirault G, Toquet C, et al. Intramyocardial delivery of mesenchymal stem cell-seeded hydrogel preserves cardiac function and attenuates ventricular remodeling after myocardial infarction. PLoS One. 2012;7(12):e51991.
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11(5):255–265.
   PubMed Web of Science ®Google Scholar
• French BA, Kramer CM. Mechanisms of post-infarct left ventricular remodeling. Drug Discov Today Dis Mech. 2007;4(3):185–196.
   PubMedGoogle Scholar
• Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res. 2006;69(3):604–613.
   Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81(4):1161–1172.
   PubMed Web of Science ®Google Scholar
• St John Sutton M, Pfeffer MA, Moye L, et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation. 1997;96(10):3294–3299.
   Web of Science ®Google Scholar
• Trueblood NA, Xie Z, Communal C, et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res. 2001;88(10):1080–1087.
   Web of Science ®Google Scholar
• Czubryt MP. Common threads in cardiac fibrosis, infarct scar formation, and wound healing. Fibrogenesis Tissue Repair. 2012;5(1):19.
   Google Scholar
• Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia. 1971;27(5):549–550.
   PubMedGoogle Scholar
• Vracko R, Thorning D. Contractile cells in rat myocardial scar tissue. Lab Invest. 1991;65(2):214–227.
   Web of Science ®Google Scholar
• Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol. 1995;147(2):325–338.
   Web of Science ®Google Scholar
• Iyer RP, de Castro Bras LE, Jin YF, Lindsey ML. Translating Koch’s postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res. 2014;114(5):860–871.
   Web of Science ®Google Scholar
• Iyer RP, Patterson NL, Zouein FA, et al. Early matrix metalloproteinase- 12 inhibition worsens post-myocardial infarction cardiac dysfunction by delaying inflammation resolution. Int J Cardiol. 2015;185:198–208.
   PubMed Web of Science ®Google Scholar
• Ma Y, Halade GV, Zhang J, et al. Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res. 2013;112(4):675–688.
   Web of Science ®Google Scholar
• de Castro Brás LE, Cates CA, DeLeon-Pennell KY, et al. Citrate synthase is a novel in vivo matrix metalloproteinase-9 substrate that regulates mitochondrial function in the postmyocardial infarction left ventricle. Antioxid Redox Signal. 2014;21(14):1974–1985.
   PubMed Web of Science ®Google Scholar
• Halade GV, Jin YF, Lindsey ML. Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther. 2013;139(1):32–40.
   PubMed Web of Science ®Google Scholar
• Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation. 1999;99(23):3063–3070.
   PubMed Web of Science ®Google Scholar
• Lindsey ML, Gannon J, Aikawa M, et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation. 2002;105(6):753–758.
   Web of Science ®Google Scholar
• Mukherjee R, Brinsa TA, Dowdy KB, et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003;107(4):618–625.
   Web of Science ®Google Scholar
• Yarbrough WM, Mukherjee R, Escobar GP, et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation. 2003;108(14):1753–1759.
   Web of Science ®Google Scholar
• Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest. 2005;115(3):599–609.
   Web of Science ®Google Scholar
• Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5(10):1135–1142.
   PubMed Web of Science ®Google Scholar
• Lindsey ML, Escobar GP, Dobrucki LW, et al. Matrix metalloproteinase- 9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;290(1):H232–H239.
   Web of Science ®Google Scholar
• Zamilpa R, Ibarra J, de Castro Brás LE, et al. Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J Mol Cell Cardiol. 2012;53(5):599–608.
   Web of Science ®Google Scholar
• Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106(1):55–62.
   PubMed Web of Science ®Google Scholar
• Ramirez TA, Iyer RP, Ghasemi O, et al. Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects. J Mol Cell Cardiol. 2014;72:326–335.
   Web of Science ®Google Scholar
• Podesser BK, Siwik DA, Eberli FR, et al. ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. Am J Physiol Heart Circ Physiol. 2001;280(3):H984–H991.
   Web of Science ®Google Scholar
• Phatharajaree W, Phrommintikul A, Chattipakorn N. Matrix metalloproteinases and myocardial infarction. Can J Cardiol. 2007;23(9):727–733.
   Web of Science ®Google Scholar
• DeCoux A, Lindsey ML, Villarreal F, Garcia RA, Schulz R. Myocardial matrix metalloproteinase-2: inside out and upside down. J Mol Cell Cardiol. 2014;77:64–72.
   Web of Science ®Google Scholar
• Papadopoulos DP, Economou EV, Makris TK, et al. Effect of angiotensin-converting enzyme inhibitor on collagenolytic enzyme activity in patients with acute myocardial infarction. Drugs Exp Clin Res. 2004;30(2):55–65.
   Google Scholar
• Yamamoto D, Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors. Curr Med Chem. 2009;16(11):1349–1354.
   Web of Science ®Google Scholar
• Yamamoto D, Takai S, Jin D, Inagaki S, Tanaka K, Miyazaki M. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol. 2007;43(6):670–676.
   Web of Science ®Google Scholar
• Yamamoto D, Takai S, Miyazaki M. Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site. Biochem Biophys Res Commun. 2007;354(4):981–984.
   Web of Science ®Google Scholar
• Ikonomidis JS, Hendrick JW, Parkhurst AM, et al. Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol. 2005;288(1):H149–H158.
   PubMed Web of Science ®Google Scholar
• Creemers EE, Davis JN, Parkhurst AM, et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol. 2003;284(1):H364–H371.
   PubMed Web of Science ®Google Scholar
• Kandalam V, Basu R, Abraham T, et al. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res. 2010;106(4):796–808.
   Web of Science ®Google Scholar
• Kandalam V, Basu R, Abraham T, et al. Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction. Am J Physiol Heart Circ Physiol. 2010;299(4):H1012–H1023.
   Web of Science ®Google Scholar
• Koskivirta I, Kassiri Z, Rahkonen O, et al. Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J Biol Chem. 2010;285(32):24487–24493.
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110(1):159–173.
   PubMed Web of Science ®Google Scholar
• Spinale FG, Mukherjee R, Zavadzkas JA, et al. Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J Biol Chem. 2010;285(39):30316–30327.
   Web of Science ®Google Scholar